Human African Trypanosomiasis Progress and Stagnation

被引：37
作者：
Bottieau, Emmanuel [1 ]
Clerinx, Jan [1 ]
机构：
[1] Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2019年 / 33卷 / 01期
关键词：
Human African trypanosomiasis; Trypanosoma brucei gambiense; Trypanosoma brucei rhodesiense; Clinical presentation; Diagnosis; Treatment; BRUCEI-GAMBIENSE TRYPANOSOMIASIS; EFLORNITHINE COMBINATION THERAPY; RAPID DIAGNOSTIC-TEST; SLEEPING SICKNESS; ORAL FEXINIDAZOLE; CLINICAL-ASPECTS; MELARSOPROL; MULTICENTER; INFECTIONS;
D O I：
10.1016/j.idc.2018.10.003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Control efforts have considerably reduced the prevalence of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in West/Central Africa and to Trypanosoma brucei rhodesiense in East Africa. Management of T brucei gambiense HAT has recently improved, with new antibody-based rapid diagnostic tests suited for mass screening and clinical care, and simpler treatments, including the nifurtimox-eflornithine combination therapy and the new oral drug fexinidazole to treat the second stage of the disease. In contrast, no major advance has been achieved for the treatment of T brucei rhodesiense HAT, a zoonosis that occasionally affects short-term travelers to endemic areas.
引用
收藏
页码：61 / +
页数：18
相关论文
共 79 条
  • [11] Burrow CJ, 2016, PALAEONTOL ELECTRON, V19, P1, DOI DOI 10.26879/601
  • [12] Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination?
    Buscher, Philippe
    Bart, Jean-Mathieu
    Boelaert, Marleen
    Bucheton, Bruno
    Cecchi, Giuliano
    Chitnis, Nakul
    Courtin, David
    Figueiredo, Luisa M.
    Franco, Jose-Ramon
    Grebaut, Pascal
    Hasker, Epco
    Ilboudo, Hamidou
    Jamonneau, Vincent
    Koffi, Mathurin
    Lejon, Veerle
    MacLeod, Annette
    Masumu, Justin
    Matovu, Enock
    Mattioli, Raffaele
    Noyes, Harry
    Picado, Albert
    Rock, Kat S.
    Rotureau, Brice
    Simo, Gustave
    Thevenon, Sophie
    Trindade, Sandra
    Truc, Philippe
    Van Reet, Nick
    [J]. TRENDS IN PARASITOLOGY, 2018, 34 (03) : 197 - 207
  • [13] Büscher P, 2017, LANCET, V390, P2397, DOI [10.1016/S0140-6736(09)60829-1, 10.1016/S0140-6736(17)31510-6]
  • [14] Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study
    Buscher, Philippe
    Mertens, Pascal
    Leclipteux, Thierry
    Gilleman, Quentin
    Jacquet, Diane
    Mumba-Ngoyi, Dieudonne
    Pyana, Patient Pati
    Boelaert, Marleen
    Lejon, Veerle
    [J]. LANCET GLOBAL HEALTH, 2014, 2 (06): : E359 - E363
  • [15] Rapid Diagnostic Test for Sleeping Sickness
    Buscher, Philippe
    Gilleman, Quentin
    Lejon, Veerle
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (11) : 1069 - 1070
  • [16] Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis
    Chappuis, F
    Udayraj, N
    Stietenroth, K
    Meussen, A
    Bovier, PA
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (05) : 748 - 751
  • [17] Options for field diagnosis of human African trypanosomiasis
    Chappuis, F
    Loutan, L
    Simarro, P
    Lejon, V
    Büscher, P
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (01) : 133 - +
  • [18] Oral fexinidazole for human African trypanosomiasis
    Chappuis, Francois
    [J]. LANCET, 2018, 391 (10116) : 100 - 102
  • [19] Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis
    Checchi F.
    Funk S.
    Chandramohan D.
    Haydon D.T.
    Chappuis F.
    [J]. BMC Research Notes, 8 (1)
  • [20] Estimates of the duration of the early and late stage of gambiense sleeping sickness
    Checchi, Francesco
    Filipe, Joao A. N.
    Haydon, Daniel T.
    Chandramohan, Daniel
    Chappuis, Francois
    [J]. BMC INFECTIOUS DISEASES, 2008, 8 (1)
12345678